Article

Ending DIR Fees Could Save Medicare Billions Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. It’s Not ‘Just A Uterine Fibroid’

In part 1 of 2, Beth Wallace shares her journey leading up to her diagnosis with leiomyosarcoma. Read more…

4. Rapid Hepatitis C Testing Improves Quality of Life Among Young Adults

Same-day results increase the number of individuals who get tested and treated for HCV. Read more…

3. FDA Approves Abemaciclib for Advanced, Metastatic Breast Cancer

Verzenio can be administered as a stand-alone treatment to patients previously treated with endocrine therapy and chemotherapy. Read more…

2. Humira Litigation Comes to a Close, Clearing Path to Biosimilar Launch

AbbVie grants commercialization rights to Amjevita. Read more…

1. Study: Ending DIR Fees Could Save Medicare Billions

The Improving Transparency and Accuracy in Medicare Part D Spending Act would end direct and indirect remuneration fees. Read more…

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards